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Abstract
Introduction
•Although the disease process is relatively well understood, 
suspicion of chronic or re-infection in Lyme disease persists.
•Diagnosis and treatment of Lyme disease and its 
complications has been a source of debate and confusion for 
providers and patients alike. The purpose of this study is to 
investigate the effectiveness and efficacy of antibiotic 
therapy in neurologic Lyme disease treatment to define best 
practice guidelines in treating such patients.
Research Questions
Literature Review
Applicability to Clinical Practice
Discussion
• Lyme disease is caused by human infection with Borrelia 
burgdorferi, a spirochete transmitted by the Ixodes tick 
which is indigenous primarily to an increasingly large area 
of the Northeast and Midwest United States. 
• Manifestations of Lyme disease vary greatly, and can result 
in significant neurologic symptoms associated with 
complications of neuroborreliosis or neurologic Lyme 
disease. 
• Diagnosis and treatment of Lyme disease and its 
complications has been a source of debate and confusion 
for providers and patients alike. 
• The purpose of this study was to investigate the 
effectiveness and efficacy of antibiotic therapy in patients 
with symptoms of neurologic Lyme disease.
• Through a review of literature related to the treatment 
and outcomes of neurologic Lyme disease, it is determined 
that current evidence based guidelines for 
pharmacological treatment of neurologic Lyme disease are 
appropriate when administered correctly. It is also 
concluded that long term antibiotic therapy is not 
appropriate for patients with symptoms of chronic Lyme 
disease due to inadequate evidence to support improved 
outcomes after antibiotic treatments.
Statement of the Problem
References
The best methods of diagnosis and treatment of neurologic 
symptoms in Lyme disease remain poorly understood, and 
therefore differing schools of thought exist regarding the 
efficacy, timing, and benefit of antibiotic therapy in patients 
with symptoms of neurologic Lyme disease. 
• In patients with neurologic Lyme disease, does the 
benefit of treating with antibiotics outweigh the 
potential for adverse reactions and resistance to 
antibiotics?
• Which antibiotics are most effective in treating 
neurologic Lyme disease?
Antibiotic Therapy
• The recommendations for treatment of neurologic Lyme 
disease are dependent on the duration of symptoms and 
physical exam with IV ceftriaxone 2g or cefotaxime 2 g 
daily for 10-28 days or penicillin G 18-24 mega U per day 
for 10-28 days. (Wormser et al., 2006).   
• Recommended prophylactic treatment of Lyme disease 
consists of a single 200 mg oral dose of doxycycline when 
appropriate criteria have been met. (Wormser et al., 
2006)
• Antibiotic therapy has not proven to be useful and is not 
recommended for patients with chronic (>6 months) 
subjective symptoms after recommended treatment 
regimens for Lyme disease” (Lantos et al. 2010).
• Klempner et al. (2001) concluded that there was no 
significant symptomatic improvement over placebo after 
30 days of treatment with ceftriaxone followed by 60 
days of doxycycline 100 mg twice daily in patients with 
symptoms of disseminated Lyme disease.
• Sopi et al. (2011),  concluded that antibiotics have 
varying effects on different forms of Borrelia burgdorferi, 
but there is little evidence of morphologic variants 
persisting in vivo, thus altering antimicrobial treatments 
to cover for such pathogens is not supported.
• Conventional and commonly used monotherapy with 
doxycycline and ceftriaxone demonstrated to be the most 
effective against the most predominant spirochete form. 
(Feng et al. 2015) 
• Kaplan et al. (2003), found no significant differences (z 
scores of <-1) for any neuropsychological tests between 
treatment and placebo groups.
Pathophysiology
• It has been recognized that B. burdorferi causes chronic 
infection as the bacteria has been isolated in skin, CSF, 
synovial tissue, blood, synovial tissue, eye tissue and 
myocardium. (Kaiser 1998)
• A classic triad of conditions in neurologic Lyme 
manifestations is said to exist including meningitis, cranial 
neuropathy, and radicular neuropathy although the 
conditions do not always occur together. (Wright, Riedel, 
Talwani, & Gilliam, 2012)
• There is little evidence to support the role of Borrelia
burgdorferi morphologic variants in the pathogenesis of 
Lyme disease, and no evidence that they influence 
treatment outcomes. (Lantos, Auwaerter, & Wormser, 
2014)
• Cognitive impairment without direct CNS infection may 
result from Lyme encephalopathy, an immune modulated 
disorder that clears after antimicrobial therapy and is 
often confused with posttreatment or chronic Lyme 
disease for which treatment is rarely indicated. (Halperin
2014)
• Much of the controversy surrounding Lyme disease is 
centered on the efficacy of treatment, specifically 
antibiotic therapy for confirmed cases of disseminated 
Lyme disease. 
• It must be questioned whether the inherent risk of 
adverse effects with lengthy courses of IV antibiotics 
outweigh the possible benefit if the improvement in 
symptoms is not statistically significant
• There is concern of adverse effects and increasing cost of 
treatment with doxycycline as prophylaxis of disease 
when clinical presentation suggests infection is unlikely.
• Disseminated symptoms are not effectively treated with 
extended antibiotic treatment. 
• No studies have confirmed the existence of morphologic 
variants of B. burgdorferi contributing to disease 
processes in human subjects.
• There is no evidence based argument to be made for 
long term antibiotic treatment of chronic symptoms 
attributed to infection with Borrelia burgdorferi .
• Providing proper patient education on the topic may 
contribute to avoidance of confusion and reduce anxiety
• Erythema migrans rash is helpful in suspicion of Lyme 
disease, but other symptoms such as neuralgias, myalgias 
and other disseminated symptoms are easily overlooked 
or misdiagnosed. 
• As healthcare providers it is our obligation to effectively 
assess, diagnose and treat our patients in a manner that 
will best serve the patient without the risk of 
contributing any undue harm.
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